Glaukos Q3 sales rise 58% to $211M; raises outlook

At the latest foreign currency exchange rates, Glaukos raised 2026 sales guidance to $775 million–$785 million and introduced preliminary 2027 guidance of $1 billion.

Rhea-AI Filing Summary

Glaukos Corporation reported third-quarter 2026 net sales of $211.0 million, up 58% year over year on reported and constant currency bases. GAAP net income was $2.018 million, compared with a $16.231 million loss in Q3 2025; non-GAAP net income was $28.5 million, and non-GAAP diluted EPS was $0.47. GAAP gross margin was 85.2%, versus 78.4%; non-GAAP gross margin was 87.7%, versus 83.9%.

U.S. Glaucoma sales were $118.6 million, up 47% year over year, including approximately $76 million from iDose TR. Corneal Health sales were $59.0 million, up 154%, including approximately $53 million from Epioxa. SG&A expenses were $130.9 million, up 58% year over year, and R&D expenses were $48.1 million, up 26%. Cash, cash equivalents, short-term investments and restricted cash totaled $339.8 million at September 30, 2026; Glaukos reported no debt.

Glaukos raised 2026 net sales guidance to $775 million to $785 million from $680 million to $700 million, based on the latest foreign currency exchange rates. It introduced preliminary 2027 net sales guidance of $1 billion, also based on the latest foreign currency exchange rates.

3 points · 1 major

PositiveiHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

0 major · 0 points

Hollow bars mark forward-looking points. How the balance works

Positive

• Major point. Forward-looking: it has not happened yet and may not happen.2026 net sales guidance increased to $775 million–$785 million.
• Moderate pointQ3 net sales rose 58% to $211.0 million.
• Moderate pointQ3 GAAP net income was $2.018 million, versus a $16.231 million loss.

Negative

• None.

Filing Explained

Glaukos reports common shares outstanding of 59,168 thousand at September 30, 2026, versus 57,511 thousand at December 31, 2025; the higher share count reduces an existing holder’s percentage ownership, absent offsetting changes.

8-K Event Classification

3 items: 2.02, 7.01, 9.01

3 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

Key Figures

Q3 net sales: $211.0 million GAAP net income: $2.018 million Non-GAAP diluted EPS: $0.47 +5 more

8 metrics

Q3 net sales $211.0 million Third quarter 2026; up 58% year over year on reported and constant currency bases

GAAP net income $2.018 million Q3 2026; compared with a $16.231 million net loss in Q3 2025

Non-GAAP diluted EPS $0.47 Q3 2026; compared with a $0.16 loss per diluted share in Q3 2025

Cash, cash equivalents, short-term investments and restricted cash $339.8 million At September 30, 2026

U.S. Glaucoma sales $118.6 million Q3 2026; up 47% year over year

Corneal Health sales $59.0 million Q3 2026; up 154% year over year

2026 net sales guidance $775 million to $785 million Raised from $680 million to $700 million; based on the latest foreign currency exchange rates

Preliminary 2027 net sales guidance $1 billion Based on the latest foreign currency exchange rates

Key Terms

constant currency, non-GAAP diluted EPS, intracameral procedural pharmaceutical, mean diurnal IOP reduction, +1 more

5 terms

constant currency financial

"net sales information on a constant currency basis"

Constant currency is a way of measuring financial results that removes the effects of changes in currency exchange rates. It allows for a clearer comparison of a company's performance over time by showing what the numbers would look like if exchange rates had stayed the same. This helps investors understand whether growth comes from actual business improvements or just currency fluctuations.

non-GAAP diluted EPS financial

"non-GAAP diluted EPS of $0.47"

Non-GAAP diluted EPS (Earnings Per Share) is a measure of a company's profit allocated to each share of stock, calculated using adjusted earnings that exclude certain items like one-time expenses or gains. It provides a view of ongoing performance by removing irregular or non-recurring factors. Investors use it to better understand the company's core profitability and compare performance across different periods or companies.

intracameral procedural pharmaceutical medical

"a first-of-its-kind intracameral procedural pharmaceutical"

mean diurnal IOP reduction medical

"an 11.1 mmHg mean diurnal IOP reduction"

product-specific J-code regulatory

"Epioxa’s product-specific J-code, J2789"

Earnings Snapshot

Net sales: $211.0 million · Guidance included

Third quarter ended September 30, 2026

Net sales $211.0 million Up 58% year over year on reported and constant currency bases

GAAP net income $2.018 million Compared with a $16.231 million net loss in Q3 2025

Non-GAAP net income $28.5 million Compared with a $9.2 million net loss in Q3 2025

GAAP diluted EPS $0.03 Compared with a $0.28 loss per diluted share in Q3 2025

Non-GAAP diluted EPS $0.47 Compared with a $0.16 loss per diluted share in Q3 2025

GAAP gross margin 85.2% 78.4% in Q3 2025

Non-GAAP gross margin 87.7% 83.9% in Q3 2025

Guidance

2026 net sales guidance of $775 million to $785 million, based on the latest foreign currency exchange rates; preliminary 2027 net sales guidance of $1 billion, also based on the latest foreign currency exchange rates.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much revenue did GKOS report in Q3 2026?

Glaukos reported $211.0 million in Q3 2026 net sales, up 58% year over year on reported and constant currency bases, compared with $133.5 million in Q3 2025.

What is GKOS's 2026 sales guidance?

Glaukos raised 2026 net sales guidance to $775 million to $785 million from $680 million to $700 million, based on the latest foreign currency exchange rates. Its preliminary 2027 net sales guidance is $1 billion, also based on the latest foreign currency exchange rates.

How much did iDose TR and Epioxa contribute to GKOS Q3 sales?

iDose TR generated approximately $76 million in third-quarter sales, and Epioxa generated approximately $53 million. The figures were presented within U.S. Glaucoma and Corneal Health performance, respectively.

What did GKOS report about iDose TR with cataract surgery?

Glaukos reported positive topline results from a Phase 4 randomized controlled trial evaluating iDose TR with cataract surgery. The study achieved its primary endpoint, with an 11.1 mmHg mean diurnal IOP reduction and a 3.6 mmHg incrementally superior treatment effect at three months compared with cataract surgery alone; the company reported a favorable safety profile through three months.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/28/2026 - 04:11 PM EDT Accepted by SEC EDGAR 10/28/2026 - 04:10 PM EDT Learn about SEC filing dates

false000119244800011924482026-10-282026-10-28

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 28, 2026

Glaukos Corporation

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-37463	33-0945406
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
1 Glaukos Way
Aliso Viejo, California				92656
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: (949) 367-9600

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock		GKOS		New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

On October 28, 2026, Glaukos Corporation (the “Company”) issued a press release announcing its financial results for the third quarter ended September 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.

The information contained in this Item 2.02 and in the accompanying Exhibit 99.1 shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended (the “Securities Act”), except as shall be expressly set forth by specific reference in such filing.

Item 7.01. Regulation FD Disclosure.

A Quarterly Summary containing supplemental business and financial information for the Company’s third quarter ended September 30, 2026 is furnished as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated by reference herein. A copy of the Quarterly Summary is also available in the “Financials & Filings” section of the Company’s investor relations website at https://investors.glaukos.com.

The information contained in this Item 7.01 and in the accompanying Exhibit 99.2 shall not be deemed filed for purposes of Section 18 of the Exchange Act, or incorporated by reference in any filing under the Exchange Act or the Securities Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
99.1		Press Release of Glaukos Corporation, dated October 28, 2026
99.2		Quarterly Summary of Glaukos Corporation for the third quarter ended September 30, 2026
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	GLAUKOS CORPORATION (Registrant)
	By:	/s/ Alex R. Thurman
		Name:	Alex R. Thurman
		Title:	Senior Vice President & Chief Financial Officer

Date: October 28, 2026

Exhibit 99.1

FOR IMMEDIATE RELEASE

Contact:

Chris Lewis

Vice President, Investor Relations & Corporate Affairs

clewis@glaukos.com

Glaukos Announces Third Quarter 2026 Financial Results

Aliso Viejo, CA – October 28, 2026 – Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced financial results for the third quarter ended September 30, 2026. Key highlights include:

•Record net sales of $211.0 million in Q3 2026 increased 58% year-over-year on a reported and constant currency basis.

•U.S. Glaucoma record net sales of $118.6 million in Q3 2026 increased 47% year-over-year.

•Corneal Health record net sales of $59.0 million in Q3 2026 increased 154% year-over-year.

•Gross margin of approximately 85% and non-GAAP gross margin of approximately 88% in Q3 2026.

•Net income of $2.0 million and non-GAAP net income of $28.5 million in Q3 2026.

•Diluted earnings per share (EPS) of $0.03 and non-GAAP diluted EPS of $0.47 in Q3 2026.

•Cash and cash equivalents, short-term investments, and restricted cash of $339.8 million at the end of Q3 2026, an increase of $50.5 million compared to $289.3 million at the end of Q2 2026.

•Raised 2026 net sales guidance to $775 million to $785 million, compared to $680 million to $700 million previously.

•Introduced preliminary 2027 net sales guidance of $1 billion.

“Our record third quarter results reflect successful global execution across our key global commercial and development priorities, leaving us well positioned to sustain our strong growth momentum driven by two transformational growth drivers in iDose TR and Epioxa,” said Thomas Burns, Glaukos chairman and chief executive officer. “We continue to successfully advance our robust pipeline of novel, dropless platform technologies designed to meaningfully advance the standard of care and improve outcomes for patients suffering from chronic eye diseases.”

Third Quarter 2026 Financial Results

Net sales in the third quarter of 2026 of $211.0 million increased 58% on a reported and constant currency basis, compared to $133.5 million in the same period in 2025.

Gross margin for the third quarter of 2026 was approximately 85%, compared to approximately 78% in the same period in 2025. Non-GAAP gross margin for the third quarter of 2026 was approximately 88%, compared to approximately 84% in the same period in 2025.

Selling, general and administrative (SG&A) expenses for the third quarter of 2026 increased 58% to $130.9 million, compared to $83.0 million in the same period in 2025. Non-GAAP SG&A expenses for the third quarter of 2026 increased 32% to $109.7 million, compared to $83.2 million in the same period in 2025.

GAAP and non-GAAP research and development (R&D) expenses for the third quarter of 2026 increased 26% to $48.1 million, compared to $38.1 million in the same period in 2025.

1

Income from operations in the third quarter of 2026 was $0.8 million, compared to operating loss of $16.4 million in the third quarter of 2025. Non-GAAP income from operations in the third quarter of 2026 was $27.3 million, compared to non-GAAP operating loss of $9.3 million in the third quarter of 2025.

Net income in the third quarter of 2026 was $2.0 million, or $0.03 per diluted share, compared to net loss of $16.2 million, or ($0.28) per diluted share, in the third quarter of 2025. Non-GAAP net income in the third quarter of 2026 was $28.5 million, or $0.47 per diluted share, compared to non-GAAP net loss of $9.2 million, or ($0.16) per diluted share, in the third quarter of 2025.

The company ended the third quarter of 2026 with approximately $339.8 million in cash and cash equivalents, short-term investments, and restricted cash, and no debt.

2026 Revenue Guidance

The company expects 2026 net sales to be in the range of $775 million to $785 million based on the latest foreign currency exchange rates.

2027 Preliminary Revenue Guidance

The company expects preliminary 2027 net sales to be $1 billion based on the latest foreign currency exchange rates.

Webcast & Conference Call

The company will host a conference call and simultaneous webcast today at 1:30 p.m. PT (4:30 p.m. ET) to discuss the results and provide additional information about the company’s financial outlook. A link to the webcast is available on the company’s website at http://investors.glaukos.com. To participate in the conference call, please dial 833-461-5787 (U.S.) or 585-542-9983 (international) and enter Conference ID 517868366. A replay of the webcast will be archived on the company’s website following completion of the call.

Quarterly Summary Document

The company has posted a document on its Investor Relations website under the “Financials & Filings – Quarterly Results” section titled “Quarterly Summary.” This Quarterly Summary document is designed to provide the investment community with a summarized and easily accessible reference document that details the key facts associated with the quarter, the state of the company’s business objectives and strategies, and any forward statements or guidance the company may make. This document is provided alongside the company’s earnings press release and is designed to be read by investors before the regularly scheduled quarterly conference call. It is the company’s goal that this format will make its quarterly earnings process more efficient and impactful for the investment community.

About Glaukos

Glaukos (www.glaukos.com) is an ophthalmic pharmaceutical and medical technology company focused on developing and commercializing novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. Glaukos first developed Micro-Invasive Glaucoma Surgery (MIGS) as an alternative to the traditional glaucoma treatment paradigm, launching its first MIGS device commercially in 2012. In 2024, Glaukos commenced commercial launch activities for iDose® TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical designed to deliver 24/7 glaucoma drug therapy inside the eye for extended periods of time. Glaukos also markets the only FDA-approved corneal cross-linking therapy utilizing a proprietary bio-activated pharmaceutical for the treatment of keratoconus, a rarely diagnosed corneal disorder. Glaukos continues to successfully develop and advance a robust pipeline of novel,

2

dropless platform technologies designed to meaningfully advance the standard of care and improve outcomes for patients suffering from chronic eye diseases.

Forward-Looking Statements

This communication contains “forward-looking statements” within the meaning of federal securities laws. All statements other than statements of historical facts included in this press release that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements. These statements are based on management’s current expectations, assumptions, estimates and beliefs. Although we believe that we have a reasonable basis for forward-looking statements contained herein, we caution you that they are based on current expectations about future events affecting us and are subject to risks, uncertainties and factors relating to our operations and business environment, all of which are difficult to predict and many of which are beyond our control, that may cause our actual results to differ materially from those expressed or implied by forward-looking statements in this press release. These potential risks and uncertainties that could cause actual results to differ materially from those described in forward-looking statements include, without limitation, our ability to successfully commercialize our iDose TR and Epioxa therapies; the impact of general macroeconomic conditions including foreign currency fluctuations and future public health crises; supply and/or manufacturing disruptions, including those impacting our principal revenue-producing products, including the risk of recalls or serious safety issues with our products; our ability to achieve or sustain profitability, generate sales of our commercialized products and develop and commercialize additional products; risks associated with our international operations; our ability to meet our customers’ expectations for the quality or delivery of our products; the potential for misuse of our products; our ability to manage our growth and meet customer demand; the success of our acquisitions, collaborations, in licensing agreements, joint ventures, alliances or partnerships with third parties; our ability to protect our information systems against cyber threats and cybersecurity incidents, and to comply with state, federal and foreign data privacy laws and regulations; risks related to the implementation of artificial intelligence and machine learning technologies; the availability of net operating loss tax carryforwards; changes to domestic or foreign healthcare laws or trade policies, which could impact our profitability; the high cost of regulatory compliance, including the requirements of participation in federal healthcare programs such as Medicare and Medicaid and regulations for the approval and sale and marketing of our products and of our manufacturing processes; risks related to securing or maintaining adequate coverage or reimbursement by government or third-party payors the lengthy and expensive clinical trial process and the uncertainty of timing and outcomes from any particular clinical trial or regulatory approval processes; and our ability to protect, and the expense and time-consuming nature of protecting, our intellectual property against third parties and competitors and the impact of any claims against us for infringement or misappropriation of third party intellectual property rights and any related litigation. These and other known risks, uncertainties and factors are described in detail under the caption “Risk Factors” and elsewhere in our filings with the Securities and Exchange Commission (SEC), including our Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, which was filed with the SEC on July 29, 2026, and our Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, which we expect to file on or before November 9, 2026. Our filings with the SEC are available in the Investor Section of our website at www.glaukos.com or at www.sec.gov. In addition, information about the risks and benefits of our products is available on our website at www.glaukos.com. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on the forward-looking statements in this press release, which speak only as of the date hereof. We do not undertake any obligation to update, amend or clarify these forward-looking statements whether as a result of new information, future events or otherwise, except as may be required under applicable securities law.

3

Statement Regarding Use of Non-GAAP Financial Measures

To supplement the consolidated financial results prepared in accordance with Generally Accepted Accounting Principles ("GAAP"), the Company uses certain non-GAAP historical financial measures. Management makes adjustments to the GAAP measures for items (both charges and gains) that (a) do not reflect the core operational activities of the Company, (b) are commonly adjusted within the Company's industry to enhance comparability of the Company's financial results with those of its peer group, or (c) are inconsistent in amount or frequency between periods (albeit such items are monitored and controlled with equal diligence relative to core operations) (“Non-GAAP Purposes”). The Company uses the term "Non-GAAP" to exclude certain expenses, gains and losses to achieve the Non-GAAP Purposes, including external acquisition-related costs incurred to effect a business combination; amortization of intangible assets acquired in a business combination, asset purchase transaction or other contractual relationship; impairment of goodwill and intangible assets; certain in-process R&D charges; fair value adjustments to contingent consideration liabilities and pre-acquisition contingencies arising from a business combination; integration and transition costs related to business combinations; fair market value adjustments to inventories acquired in a business combination or asset purchase transaction; restructuring charges, duplicative operating expenses, or asset write-offs (or reversals) associated with exiting or significantly downsizing a business; unusual non-recurring expenses associated with inventory write-downs; gain or loss from the sale of a business; gain or loss on the mark-to-market adjustment, impairment, or sale of long-term investments; mark-to-market adjustments on derivative instruments that hedge income or expense exposures in a future period; significant legal litigation costs and/or settlement expenses or proceeds; legal and other associated expenses that are both unusual and significant related to governmental or internal inquiries; expenses, acceleration of amortization of debt issuance costs and gain or loss on debt extinguishment associated with the exchange or redemption of convertible senior notes; significant discrete income and other tax adjustments related to transactions as well as changes in estimated acquisition-date tax effects associated with business combinations, and the impact from implementation of tax law changes and settlements; and any other adjustment that is determined to be appropriate and consistent with the Non-GAAP Purposes. See “GAAP to Non-GAAP Reconciliations” for a reconciliation of each non-GAAP measure presented to the comparable GAAP financial measure.

In addition, in order to remove the impact of fluctuations in foreign currency exchange rates, the Company also presents certain net sales information on a constant currency basis, which represents the outcome that would have resulted had exchange rates in the current period been the same as the average exchange rates in effect in the comparable prior period. See “Reported Sales vs. Prior Periods” for a presentation of certain net sales information on a reported, GAAP and a constant currency basis.

4

GLAUKOS CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(unaudited)

(in thousands, except per share amounts)

		Three Months Ended								Nine Months Ended
		September 30,								September 30,
		2026				2025				2026				2025
Net sales		$	211,030			$	133,537			$	547,211			$	364,321
Cost of sales			31,164				28,831				98,519				80,043
Gross profit			179,866				104,706				448,692				284,278
Operating expenses:
Selling, general and administrative			130,943				82,999				339,946				237,047
Research and development			48,095				38,072				143,541				106,963
Acquired in-process research and development			-				-				1,500				-
Total operating expenses			179,038				121,071				484,987				344,010
Income (loss) from operations			828				(16,365	)			(36,295	)			(59,732	)
Non-operating income (expense):
Interest income			2,493				2,552				7,203				8,202
Interest expense			(1,087	)			(1,175	)			(3,671	)			(3,489	)
Other income (expense), net			87				(1,009	)			(1,936	)			1,793
Total non-operating income			1,493				368				1,596				6,506
Income (loss) before taxes			2,321				(15,997	)			(34,699	)			(53,226	)
Income tax provision			303				234				1,443				808
Net income (loss)		$	2,018			$	(16,231	)		$	(36,142	)		$	(54,034	)
Basic net income (loss) per share		$	0.03			$	(0.28	)		$	(0.62	)		$	(0.95	)
Diluted net income (loss) per share		$	0.03			$	(0.28	)		$	(0.62	)		$	(0.95	)
Weighted-average shares outstanding used to    compute basic net income (loss) per share			59,105				57,398				58,651				57,083
Weighted-average shares outstanding used to    compute diluted net income (loss) per share			61,196				57,398				58,651				57,083

5

GLAUKOS CORPORATION

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands, except par values)

		September 30,				December 31,
		2026				2025
		(unaudited)
Assets
Current assets:
Cash and cash equivalents		$	162,327			$	90,813
Short-term investments			174,372				187,947
Accounts receivable, net			150,004				108,608
Inventory			61,032				63,564
Prepaid expenses and other current assets			31,915				24,052
Total current assets			579,650				474,984
Restricted cash			3,115				3,834
Property and equipment, net			112,068				113,253
Operating lease right-of-use asset			30,795				31,527
Finance lease right-of-use asset			37,594				39,404
Intangible assets, net			121,261				141,916
Goodwill			66,710				66,710
Deposits and other assets			28,336				21,859
Total assets		$	979,529			$	893,487
Liabilities and stockholders' equity
Current liabilities:
Accounts payable		$	24,407			$	24,624
Accrued liabilities			102,319				76,651
Total current liabilities			126,726				101,275
Operating lease liability			35,057				35,767
Finance lease liability			66,926				68,109
Deferred tax liability, net			441				441
Other liabilities			33,105				31,740
Total liabilities			262,255				237,332
Stockholders' equity:
Preferred stock, $0.001 par value; 5,000 shares authorized; no    shares issued and outstanding as of September 30, 2026 and    December 31, 2025			-				-
Common stock, $0.001 par value; 150,000 shares authorized; 59,196    and 57,539 shares issued and 59,168 and 57,511 shares    outstanding at September 30, 2026 and December 31, 2025, respectively			59				58
Additional paid-in capital			1,684,829				1,586,056
Accumulated other comprehensive income			1,790				3,303
Accumulated deficit			(969,272	)			(933,130	)
Less treasury stock (28 shares as of September 30, 2026 and December 31,    2025)			(132	)			(132	)
Total stockholders' equity			717,274				656,155
Total liabilities and stockholders' equity		$	979,529			$	893,487

6

GLAUKOS CORPORATION

GAAP to Non-GAAP Reconciliations

(in thousands, except per share amounts and percentage data)

(unaudited)

		Q3 2026												Q3 2025
		GAAP				Adjustments				Non-GAAP				GAAP				Adjustments				Non-GAAP
Cost of sales		$	31,164			$	(5,274	)	(A)	$	25,890			$	28,831			$	(7,310	)	(A) (B)	$	21,521
Gross Margin			85.2	%			2.5	%			87.7	%			78.4	%			5.5	%			83.9	%
Operating expenses:
Selling, general and administrative		$	130,943			$	(21,219	)	(C)(D)	$	109,724			$	82,999			$	243		(D)	$	83,242
Income (loss) from operations		$	828			$	26,493			$	27,321			$	(16,365	)		$	7,067			$	(9,298	)
Net income (loss)		$	2,018			$	26,493		(E)	$	28,511			$	(16,231	)		$	7,067		(E)	$	(9,164	)
Basic net income (loss) per share		$	0.03			$	0.45			$	0.48			$	(0.28	)		$	0.12			$	(0.16	)
Diluted net income (loss) per    share		$	0.03			$	0.44			$	0.47			$	(0.28	)		$	0.12			$	(0.16	)
Weighted-average shares     outstanding used to     compute basic net income     (loss) per share			59,105								59,105				57,398								57,398
Weighted-average shares     outstanding used to     compute diluted net income     (loss) per share			61,196								61,196				57,398								57,398

(A)

•Cost of sales adjustment related to amortization of developed technology intangible assets associated with the acquisition of Avedro, Inc. (Avedro) of $4.8 million in Q3 2026 and $5.5 million in Q3 2025.

•Mobius acquisition-related amortization expense of developed intellectual property of $0.5 million in Q3 2026 and Q3 2025, respectively.

(B)

•Non-recurring, non-cash charge related to the write-down of certain inventory of $1.3 million.

(C)

•Expenses of $5.9 million related to the Company’s trade secrets litigation and other litigation matters.

•Expenses of $14.1 million related to the resolution agreement with the Regents of the University of California.

•Expenses of $0.8 million associated with the integration of a major system.

(D)

•Mobius contingent consideration fair value adjustments of $0.4 million in Q3 2026 and ($0.2) million in Q3 2025.

(E)

•Includes total tax effect for non-GAAP pre-tax adjustments. For non-GAAP adjustments associated with the U.S., the tax effect is $0 given the Company's U.S. taxable loss positions in both 2026 and 2025.

7

GLAUKOS CORPORATION

GAAP to Non-GAAP Reconciliations

(in thousands, except per share amounts and percentage data)

(unaudited)

		Year-to-Date Q3 2026												Year-to-Date Q3 2025
		GAAP				Adjustments				Non-GAAP				GAAP				Adjustments				Non-GAAP
Cost of sales		$	98,519			$	(19,222	)	(A)	$	79,297			$	80,043			$	(18,597	)	(A) (B)	$	61,446
Gross Margin			82.0	%			3.5	%			85.5	%			78.0	%			5.1	%			83.1	%
Operating expenses:
Selling, general and    administrative		$	339,946			$	(26,316	)	(C)(D)	$	313,630			$	237,047			$	(52	)	(D)	$	236,995
(Loss) income from operations		$	(36,295	)		$	45,538			$	9,243			$	(59,732	)		$	18,649			$	(41,083	)
Non-operating income (expense):
Interest expense		$	(3,671	)		$	369		(E)	$	(3,302	)		$	(3,489	)		$	-			$	(3,489	)
Net (loss) income		$	(36,142	)		$	45,907		(F)	$	9,765			$	(54,034	)		$	18,649		(F)	$	(35,385	)
Basic net (loss) income per share		$	(0.62	)		$	0.79			$	0.17			$	(0.95	)		$	0.33			$	(0.62	)
Diluted net (loss) income per    share		$	(0.62	)		$	0.78			$	0.16			$	(0.95	)		$	0.33			$	(0.62	)
Weighted-average shares     outstanding used to     compute basic net income     (loss) per share			58,651								58,651				57,083								57,083
Weighted-average shares     outstanding used to     compute diluted net income     (loss) per share (G)			58,651								60,598				57,083								57,083

(A)

•Cost of sales adjustment related to amortization of developed technology intangible assets associated with the acquisition of Avedro, Inc. (Avedro) of $17.8 million year-to-date Q3 2026 and $16.6 million year-to-date Q3 2025.

•Mobius acquisition-related amortization expense of developed intellectual property of $1.5 million year-to-date Q3 2026 and $0.7 million year-to-date Q3 2025.

(B)

•Non-recurring, non-cash charge related to the write-down of certain inventory of $1.3 million.

(C)

•Expenses of $9.9 million related to the Company’s trade secrets litigation and other litigation matters.

•Expenses of $14.1 million related to the resolution agreement with the Regents of the University of California.

•Expenses of $1.2 million associated with the integration of a major system.

•Provision for doubtful accounts related to the overpayment of prior period payroll withholdings of $0.7 million.

(D)

•Mobius contingent consideration fair value adjustments of $0.4 million year-to-date Q3 2026 and ($0.2) million year-to-date Q3 2025.

•Mobius acquisition-related transaction expense of $0.3 million year-to-date Q3 2025.

(E)

•Interest expense related to the untimely payment of prior period payroll withholdings

(F)

•Includes total tax effect for non-GAAP pre-tax adjustments. For non-GAAP adjustments associated with the U.S., the tax effect is $0 given the Company's U.S. taxable loss positions in both 2026 and 2025.

(G)

•Year-to-date Q3 2026 non-GAAP diluted weighted-average shares reflect the dilution effect from outstanding stock options, unvested restricted stock units, performance-based equity awards, and employee stock purchase program option shares under the treasury stock method.

8

Reported Sales vs. Prior Periods (in thousands)
										Year-over-Year Percent Change							Quarter-over-Quarter Percent Change
	3Q 2026			3Q 2025			2Q 2026			Reported			Operations (1)			Currency (2)	Reported			Operations (1)			Currency (2)
International    Glaucoma	$	33,356		$	29,443		$	36,631			13.3	%		14.6	%	(1.3%)	(8.9%)			(8.4%)			(0.5%)
Total Net Sales	$	211,030		$	133,537		$	185,610			58.0	%		58.3	%	(0.3%)		13.7	%		13.8	%	(0.1%)

(1)Operational growth excludes the effect of translational currency

(2)Calculated by converting the current period numbers using the prior period’s average foreign exchange rates

9

	Exhibit 99.2
	OCTOBER 28, 2026

GLAUKOS CORPORATION (NYSE: GKOS)

THIRD QUARTER 2026 IN REVIEW

Important Information

This document is intended to be read by investors in advance of regularly scheduled quarterly conference calls and was designed to provide a review of Glaukos Corporation’s recent financial and operational performance and general business outlook.

Please see “Forward-Looking Statements” and “Statement Regarding Use of Non-GAAP Financial Measures” in the “Additional Information” section of this document.

Conference Call Information

Date:		October 28, 2026
Time:		4:30 p.m. ET / 1:30 p.m. PT
Dial-in numbers:		1-833-461-5787 (U.S.), 1-585-542-9983 (International)
Confirmation ID:		517 868 366
Live webcast:		Events page at the Glaukos Investor Relations website at http://investors.glaukos.com or at this link.
Webcast replay:		A replay of the webcast will be archived on the Glaukos Investor Relations website following completion of the call.

1

OCTOBER 28, 2026

THIRD QUARTER 2026 FINANCIAL RESULTS SUMMARY

Business Description	Ophthalmic pharmaceutical and medical technology company focused on developing and commercializing novel, dropless platform therapies designed to disrupt the conventional standard of care and improve outcomes for patients suffering from chronic eye diseases
Disease Categories	Glaucoma Corneal Health Retinal Disease
Revenue (Growth)	3Q 2026 $211.0 million (+58% reported and constant currency versus 3Q 2025)
Gross Margin (Non-GAAP)	3Q 2026 ~88% (versus ~84% in 3Q 2025)
Operating Income (Non-GAAP)	3Q 2026 $27.3 million (versus $9.3 million operating loss in 3Q 2025)
Net Income & EPS (Non-GAAP)	3Q 2026 Net Income $28.5 million (versus $9.2 million net loss in 3Q 2025)	3Q 2026 EPS $0.47 (versus $0.16 EPS net loss in 3Q 2025)
Cash & Cash Equivalents, Short-Term Investments, and Restricted Cash	$339.8 million as of September 30, 2026 (+$50.5 million versus $289.3 million as of June 30, 2026)
FY 2026 Sales Guidance	FY 2026 global consolidated revenues of $775 - $785 million expected
FY 2027 Preliminary Sales Guidance	FY 2027 global consolidated revenues of $1 billion expected

See “Statement Regarding Use of Non-GAAP Financial Measures” and the Non-GAAP reconciliations included within the Additional Information section of this document. Reconciliations for each of constant currency revenue growth, Non-GAAP Gross Margin, and the other non-GAAP financial measures disclosed in this document to the most directly comparable GAAP financial measure are provided.

2

OCTOBER 28, 2026

Revenue Performance & Commercial Overview

Global Consolidated Revenue Performance

Glaukos reported record third quarter net revenues of $211.0 million that were up 58% on a reported and constant currency basis, versus 3Q 2025. Our third quarter record results reflect a sustained growth acceleration in our business with the strong performance driven by growing iDose® TR adoption and utilization, along with our broader Interventional Glaucoma, or IG, initiatives globally, as well as growing contributions of Epioxa®.

Franchise Revenue Performance

3

OCTOBER 28, 2026

U.S. Glaucoma

Our record third quarter U.S. Glaucoma net revenues were approximately $118.6 million, representing year-over-year growth of 47% versus 3Q 2025 driven by growing contributions from iDose TR, which generated sales of approximately $76 million in the third quarter.

During the third quarter, we successfully advanced execution of our commercialization of iDose TR, a first-of-its-kind intracameral procedural pharmaceutical that was designed to continuously deliver glaucoma drug therapy for up to three years. Most importantly, iDose TR continues to deliver strong clinical outcomes that meaningfully improve patients’ lives, resulting in strong physician interest and adoption while helping to accelerate a broader treatment paradigm shift toward earlier, interventional glaucoma care.

International Glaucoma

Our third quarter International Glaucoma net revenues were approximately $33.4 million, representing year-over-year growth of 13% on a reported basis, or 15% on a constant currency basis, versus 3Q 2025. The strong growth internationally during the third quarter was broad-based as we continue to scale our international infrastructure and increasingly drive MIGS forward as the standard of care in each region and major market in the world.

We remain in the early stages of expanding our IG and product portfolio initiatives globally ahead of anticipated new product approvals and expanding market access in the years to come.

Corneal Health

Our record third quarter Corneal Health net revenues were approximately $59.0 million, representing year-over-year growth of 154% versus 3Q 2025, including Epioxa net sales of approximately $53 million.

During the third quarter, we advanced our initial commercial launch plans for Epioxa, our novel, groundbreaking advancement in corneal cross-linking for the treatment of keratoconus, a rare, sight-threatening disease that is currently far too often undiagnosed and untreated. We believe Epioxa represents a transformative innovation in keratoconus care, offering an incision-free alternative to traditional corneal cross-linking procedures as it does not require the removal of the corneal epithelium, the outermost layer of the front of the eye. This novel, oxygen-enriched topical therapeutic, bioactivated by UV light, is designed to reduce the pain associated with removal of the epithelium, streamline the procedure, and minimize recovery, all while delivering clinically meaningful outcomes and exceptional value to patients, providers, and the healthcare system.

As the first and only FDA-approved epithelium-on corneal cross-linking therapy for keratoconus, Epioxa has been met with strong interest from surgeons and the broader ophthalmic community, reinforcing our confidence in its potential to redefine the treatment paradigm for this rare, sight-threatening disease.

We will continue to focus on expanding access for keratoconus patients suffering from this rarely diagnosed disease.

4

OCTOBER 28, 2026

Additional Commercial Updates & Commentary

We have had several additional positive commercial updates worth highlighting here:

✓Advanced commercial launch activities in the U.S. for iDose TR

oGrowing number of trained surgeons and accounts

oIncreasing utilization by the installed active surgeon base

oBroadening and streamlining market access among MACs, commercial, and Medicare Advantage payers

oExpanded set of peer-reviewed literature, now consisting of 27 different peer-reviewed publications highlighting iDose TR as a transformative new treatment alternative for patients suffering with glaucoma and ocular hypertension

oAccelerating marketing investments to support increased patient awareness and education

✓Advanced initial commercial launch plans for Epioxa

oEpioxa commercial availability announced March 19, 2026

oSuccessfully established, and continue to selectively expand, a broad-reaching site-of-care network, with acquired O2N systems already actively deployed at locations covering roughly 90% of the U.S. population, and a broader pipeline of systems moving through approval processes that would expand our treatment reach to more than 95%

oMarket access:

▪Advancing efforts with payors to secure access pathways and policy coverage for Epioxa, with access pathways now established for approximately 90% of commercial lives in the U.S., including with the 5 largest payors, and more than 80% of Medicaid lives, reflecting encouraging receptivity of Epioxa’s clinical value

▪We remain committed to securing access pathways with the remaining smaller and regional plans as we increasingly focus on pathway optimization and improving the time-to-treatment for patients

▪Following the July 1, 2026 effective date of Epioxa’s product-specific J-code, J2789, we made encouraging progress during the third quarter in optimizing the operational processes supporting reporting and reimbursement. We remain focused on working

5

OCTOBER 28, 2026

with providers and our specialty pharmacy partner to further refine these workflows and facilitate a more efficient and predictable reimbursement process for Epioxa.

	oDeployed various new patient services and support programs
	oLaunched Could it be KC? disease awareness and educational campaign in partnership with NBA champion Stephen Curry to raise awareness, educate patients and families, and promote earlier detection and diagnosis
	oAdvancing targeted marketing and DTC campaigns designed to significantly enhance awareness, education, and detection, supported by greater optometric engagement and strengthened advocacy partnerships
	oExpanded new financial co-pay assistance program and operationalized Specialty Pharmacy partner network in support of Epioxa patients

✓CMS’s Proposed Rules for Calendar Year 2027

oHospital Outpatient Prospective Payment System (OPPS) and Ambulatory Surgical Center (ASC) Facility Fee Schedules: Proposed to maintain the 2026 APC assignments and largely maintain facility fee rates associated with our procedures across both the hospital outpatient and ASC settings.

oPhysician Fee Schedule (PFS) updates: Proposed modest reductions in physician fee reimbursement for several Category 1 CPT codes across ophthalmology, including for cataract and surgical MIGS procedures specifically.

6

OCTOBER 28, 2026

2026 Revenue Guidance Raised to Reflect Strong Momentum

Glaukos now expects full-year 2026 global consolidated net sales of $775 - $785 million, up from its previous guidance of $680 - $700 million. This guidance attempts to take into consideration:

•Potential growing contributions from Epioxa as commercial launch plans advance and more streamlined access pathways are solidified operationally

•Potential growing contributions from iDose TR as market access initiatives progress and broader IG initiatives take hold

•Potential growing contributions from iStent infinite as broader IG initiatives take hold

•Uncertainties associated with five MAC’s proposed LCDs for iDose TR

•Combo-cataract MIGS competition globally

•The continued estimated impact on U.S. Glaucoma volumes related to professional fee reimbursement for combination-cataract trabecular bypass surgery versus other more invasive alternatives

•The latest foreign currency exchange spot rates as of our 3Q 2026 earnings call on October 28, 2026

•Global macroeconomic and geopolitical environment and associated uncertainties, which at this time are difficult to predict

7

OCTOBER 28, 2026

Research & Development / Pipeline Overview

Pipeline Summary

Our five key dropless technology therapy platforms designed to disrupt traditional treatment paradigms and generate cascades of future innovation are as follows:

•iStent® micro-scale surgical devices

•iDose® sustained-release procedural pharmaceuticals

•iLink® bio-activated pharmaceuticals

•iLution™ transdermal pharmaceuticals

•Retina XR bio-erodible sustained-release pharmaceuticals

8

OCTOBER 28, 2026

Key R&D and Pipeline Updates

We continue to advance a broad and differentiated clinical pipeline across our five novel therapeutic platforms, encompassing 14 publicly disclosed programs and additional undisclosed assets, supported by a robust portfolio of active clinical and Phase 4 studies. Recent updates in our pipeline include:

iDose Platform Updates

✓Announced U.S. FDA approval for NDA labeling supplement allowing for unlimited re-administration of iDose TR in patients who maintain a healthy cornea (January 2026)

✓Advancing Phase 2b/3 clinical program for iDose TREX, our next-generation iDose therapy

oInitial results of Phase 2a clinical trial demonstrated substantial IOP reductions of 8.6 to 10.8 mmHg through 3 months

✓Advancing Phase 3b clinical program for iDose TRIO

oInitial human factors study indicated strong user preference (~90% favorability)

✓Announced positive topline results from our Phase 4 randomized controlled trial evaluating iDose TR in combination with cataract surgery (October 2026)

oThe study achieved its primary endpoint, demonstrating statistically significant superiority and a clinically meaningful IOP reduction compared to cataract surgery alone, with an 11.1 mmHg mean diurnal IOP reduction and a 3.6 mmHg incrementally superior treatment effect at 3 months

oFavorable safety profile through three months

✓Advancing various Phase 4 studies for iDose TR

9

	Exhibit 99.2
	OCTOBER 28, 2026

iLink Platform Updates

✓Announced U.S. FDA approval for Epioxa (Epi-on) (October 2025)

oEpioxa is a groundbreaking advancement in corneal cross-linking for the treatment of keratoconus, a rare, sight-threatening disease that is currently far too often undiagnosed and untreated

oEpioxa ushers in a new standard of care for patients

✓Announced positive three-year extension study results for Epioxa, which demonstrated sustained improvements in corneal shape, meaningful visual acuity gains, and a favorable long-term safety profile following a single treatment (October 2026)

oTreated eyes achieved a robust and sustained 1.9 diopter (D) improvement in maximum corneal curvature (Kmax) from baseline, reflecting meaningful long-term corneal flattening and stabilization

oTreated eyes also demonstrated clinically meaningful visual outcomes at year 3, with 29% and 20% of eyes gaining two or more and three or more lines of best-corrected visual acuity from baseline, respectively

oFavorable safety profile through 3 years

✓Advancing development of KC screening device to support planned commercialization as we enter 2027

✓Preparing to commence Phase 3 clinical program for third-generation, customized, tomography-guided iLink therapy in 2027

✓Advancing Phase 2 clinical trial for iVeena

10

	Exhibit 99.2
	OCTOBER 28, 2026

iStent Platform Updates

✓Completed patient enrollment in PMA pivotal trial for iStent infinite in mild-to-moderate glaucoma patients (4Q 2025)

✓Announced EU MDR certification for iStent infinite (June 2025)

✓Completed patient enrollment in 510(k) pivotal study for PRESERFLO™ MicroShunt (July 2026)

iLution Platform Updates

✓Completed enrollment in Phase 2 clinical trial for iLution™ Blepharitis (2Q 2026)

Retina XR Platform Updates

✓Announced exclusive license agreement with RevOpsis Therapeutics for RO-104, which was assigned Glaukos development code GLK-901, a first-in-class tri-specific biologic, as well as exclusive rights to the proprietary RevMod platform to discover and develop up to four additional next-generation multi-specific biologics for retinal diseases (October 2026)

✓Completed patient enrollment in first-in-human Retina XR clinical development program for IVT multi-kinase inhibitor in wet AMD patients (GLK-401) (4Q 2025)

11

OCTOBER 28, 2026

Product / Pipeline Chart

12

OCTOBER 28, 2026

Other Financial Performance Overview

As a reminder, we discuss our financial performance on a non-GAAP basis and summarize our GAAP performance. We encourage investors to review our GAAP to non-GAAP reconciliation which can be found in our earnings press release, the Additional Information section contained herein, as well as the Investor Relations section of our website.

Third quarter 2026 financial performance summary:

	3Q 2026: 88% 3Q 2025: 84% YoY ∆: +385 bps	•Please note that our non-GAAP adjustments to cost of goods sold include substantial amounts related to Avedro and Mobius acquisitions accounting
	3Q 2026: $109.7M 3Q 2025: $83.2M YoY ∆: +32%	•(-2%) sequential decrease vs $111.7M in 2Q 2026 •YoY increase primarily reflects commercial and G&A investments globally and new product launch activities
	3Q 2026: $48.1M 3Q 2025: $38.1M YoY ∆: +26%	•(-6%) sequential decrease vs $51.3M in 2Q 2026 •YoY increase primarily reflects continued investment in and advancement of R&D programs and clinical trials
	3Q 2026: $157.8M 3Q 2025: $121.3M YoY ∆: +30%	•(-3%) sequential decrease vs $163.0M in 2Q 2026
	Operating Income (Loss) 3Q 2026 $27.3M 3Q 2025: ($9.3M) Net Income (Loss) 3Q 2026: $28.5M 3Q 2025: ($9.2M) Diluted EPS (Loss) 3Q 2026: $0.47 3Q 2025: ($0.16)
	3Q 2026: $2.1M 3Q 2025: $1.6M YoY ∆: +$0.5M	•Capital expenditures reflect normal course spend primarily on business maintenance activities and equipment upgrades
	3Q 2026: $339.8M 2Q 2026: $289.3M QoQ ∆: +$50.5M

13

OCTOBER 28, 2026

Other Important Updates

➢While we believe our business is increasingly well positioned to deliver sustained cash generation and profitability as we scale, we remind investors that our primary focus remains on maximizing near- and long-term revenue growth and capitalizing on the significant opportunities in front of us. Accordingly, we remain committed to investing strategically across our industry-leading pipeline, commercial infrastructure, and market development initiatives to advance our innovation platforms, expand our addressable markets, and drive sustained top-line growth. We will continue to manage the business thoughtfully, balancing these strategic investments with disciplined expense management, capital allocation, and a focus on operational efficiency. Ultimately, we believe this approach best positions us to bring transformative therapies to patients, strengthen our financial profile, and drive sustainable, substantial long-term growth and shareholder value.

➢Given the ongoing conversations around tariff and broader geopolitical volatility, we wanted to reiterate that we manufacture and source our products primarily within the U.S., and as such, expect minimal direct exposure to the most recently implemented tariff-related policies. That said, the global tariff environment remains fluid, and more broadly, the current geopolitical backdrop and macroeconomic uncertainties continue to evolve. As such, we will continue to closely monitor these situations given the overall instability in the marketplace and global macroeconomic uncertainties.

14

OCTOBER 28, 2026

Additional Information

15

OCTOBER 28, 2026

Forward-Looking Statements

This communication contains “forward-looking statements” within the meaning of federal securities laws. All statements other than statements of historical facts included in this presentation that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements. These statements are based on management’s current expectations, assumptions, estimates and beliefs. Although we believe that we have a reasonable basis for forward-looking statements contained herein, we caution you that they are based on current expectations about future events affecting us and are subject to risks, uncertainties and factors relating to our operations and business environment, all of which are difficult to predict and many of which are beyond our control, that may cause our actual results to differ materially from those expressed or implied by forward-looking statements in this presentation. These potential risks and uncertainties that could cause actual results to differ materially from those described in forward-looking statements include, without limitation, our ability to successfully commercialize our iDose TR and Epioxa therapies; the impact of general macroeconomic conditions including foreign currency fluctuations and future public health crises; supply and/or manufacturing disruptions, including those impacting our principal revenue-producing products, including the risk of recalls or serious safety issues with our products; our ability to achieve or sustain profitability, generate sales of our commercialized products and develop and commercialize additional products; risks associated with our international operations; our ability to meet our customers’ expectations for the quality or delivery of our products; the potential for misuse of our products; our ability to manage our growth and meet customer demand; the success of our acquisitions, collaborations, in licensing agreements, joint ventures, alliances or partnerships with third parties; our ability to protect our information systems against cyber threats and cybersecurity incidents, and to comply with state, federal and foreign data privacy laws and regulations; risks related to the implementation of artificial intelligence and machine learning technologies; the availability of net operating loss tax carryforwards; changes to domestic or foreign healthcare laws or trade policies, which could impact our profitability; the high cost of regulatory compliance, including the requirements of participation in federal healthcare programs such as Medicare and Medicaid and regulations for the approval and sale and marketing of our products and of our manufacturing processes; risks related to securing or maintaining adequate coverage or reimbursement by government or third-party payors the lengthy and expensive clinical trial process and the uncertainty of timing and outcomes from any particular clinical trial or regulatory approval processes; and our ability to protect, and the expense and time-consuming nature of protecting, our intellectual property against third parties and competitors and the impact of any claims against us for infringement or misappropriation of third party intellectual property rights and any related litigation. These and other known risks, uncertainties and factors are described in detail under the caption “Risk Factors” and elsewhere in our filings with the Securities and Exchange Commission (SEC), including our Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, which was filed with the SEC on July 29, 2026, and our Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, which we expect to file on or before November 9, 2026. Our filings with the SEC are available in the Investor Section of our website at www.glaukos.com or at www.sec.gov. In addition, information about the risks and benefits of our products is available on our website at www.glaukos.com. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on the forward-looking statements in this press release, which speak only as of the date hereof. We do not undertake any obligation to update, amend or

16

OCTOBER 28, 2026

clarify these forward-looking statements whether as a result of new information, future events or otherwise, except as may be required under applicable securities law.

Statement Regarding Use of Non-GAAP Financial Measures

To supplement the consolidated financial results prepared in accordance with Generally Accepted Accounting Principles ("GAAP"), the Company uses certain non-GAAP historical financial measures. Management makes adjustments to the GAAP measures for items (both charges and gains) that (a) do not reflect the core operational activities of the Company, (b) are commonly adjusted within the Company's industry to enhance comparability of the Company's financial results with those of its peer group, or (c) are inconsistent in amount or frequency between periods (albeit such items are monitored and controlled with equal diligence relative to core operations) (“Non-GAAP Purposes”). The Company uses the term "Non-GAAP" to exclude certain expenses, gains and losses to achieve the Non-GAAP purposes, including external acquisition-related costs incurred to effect a business combination; amortization of intangible assets acquired in a business combination, asset purchase transaction or other contractual relationship; impairment of goodwill and intangible assets; certain in-process R&D charges; fair value adjustments to contingent consideration liabilities and pre-acquisition contingencies arising from a business combination; integration and transition costs related to business combinations; fair market value adjustments to inventories acquired in a business combination or asset purchase transaction; restructuring charges, duplicative operating expenses, or asset write-offs (or reversals) associated with exiting or significantly downsizing a business; unusual non-recurring expenses associated with inventory write-downs; gain or loss from the sale of a business; gain or loss on the mark-to-market adjustment, impairment, or sale of long-term investments; mark-to-market adjustments on derivative instruments that hedge income or expense exposures in a future period; significant legal litigation costs and/or settlement expenses or proceeds; legal and other associated expenses that are both unusual and significant related to governmental or internal inquiries; expenses, acceleration of amortization of debt issuance costs and gain or loss on debt extinguishment with the exchange or redemption of convertible senior notes; and significant discrete income and other tax adjustments related to transactions as well as changes in estimated acquisition-date tax effects associated with business combinations, and the impact from implementation of tax law changes and settlements; and any other adjustment that is determined to be appropriate and consistent with the Non-GAAP Purposes. See “Primary GAAP to Non-GAAP Reconciliations” for a reconciliation of each non-GAAP measure presented to the comparable GAAP financial measure. Beginning in the second quarter of 2022, we no longer exclude certain upfront and contingent milestone payments in connection with collaborative and licensing arrangements and certain in-process R&D charges for non-GAAP reporting and disclosure purposes.

In addition, in order to remove the impact of fluctuations in foreign currency exchange rates, the Company also presents certain net sales information on a constant currency basis, which represents the outcome that would have resulted had exchange rates in the current period been the same as the average exchange rates in effect in the comparable prior period. See “Additional GAAP to Non-GAAP Reconciliations” for a presentation of certain net sales information on a reported, GAAP and a constant currency basis.

17

OCTOBER 28, 2026

GAAP Income Statement

GLAUKOS CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(unaudited)

(in thousands, except per share amounts)

		Three Months Ended								Nine Months Ended
		September 30,								September 30,
		2026				2025				2026				2025
Net sales		$	211,030			$	133,537			$	547,211			$	364,321
Cost of sales			31,164				28,831				98,519				80,043
Gross profit			179,866				104,706				448,692				284,278
Operating expenses:
Selling, general and administrative			130,943				82,999				339,946				237,047
Research and development			48,095				38,072				143,541				106,963
Acquired in-process research and development			-				-				1,500				-
Total operating expenses			179,038				121,071				484,987				344,010
Income (loss) from operations			828				(16,365	)			(36,295	)			(59,732	)
Non-operating income (expense):
Interest income			2,493				2,552				7,203				8,202
Interest expense			(1,087	)			(1,175	)			(3,671	)			(3,489	)
Other income (expense), net			87				(1,009	)			(1,936	)			1,793
Total non-operating income			1,493				368				1,596				6,506
Income (loss) before taxes			2,321				(15,997	)			(34,699	)			(53,226	)
Income tax provision			303				234				1,443				808
Net income (loss)		$	2,018			$	(16,231	)		$	(36,142	)		$	(54,034	)
Basic net income (loss) per share		$	0.03			$	(0.28	)		$	(0.62	)		$	(0.95	)
Diluted net income (loss) per share		$	0.03			$	(0.28	)		$	(0.62	)		$	(0.95	)
Weighted-average shares outstanding used to compute     basic net income (loss) per share			59,105				57,398				58,651				57,083
Weighted-average shares outstanding used to compute     diluted net income (loss) per share			61,196				57,398				58,651				57,083

18

OCTOBER 28, 2026

GAAP Balance Sheet

GLAUKOS CORPORATION

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands, except par values)

		September 30,				December 31,
		2026				2025
		(unaudited)
Assets
Current assets:
Cash and cash equivalents		$	162,327			$	90,813
Short-term investments			174,372				187,947
Accounts receivable, net			150,004				108,608
Inventory			61,032				63,564
Prepaid expenses and other current assets			31,915				24,052
Total current assets			579,650				474,984
Restricted cash			3,115				3,834
Property and equipment, net			112,068				113,253
Operating lease right-of-use asset			30,795				31,527
Finance lease right-of-use asset			37,594				39,404
Intangible assets, net			121,261				141,916
Goodwill			66,710				66,710
Deposits and other assets			28,336				21,859
Total assets		$	979,529			$	893,487
Liabilities and stockholders' equity
Current liabilities:
Accounts payable		$	24,407			$	24,624
Accrued liabilities			102,319				76,651
Total current liabilities			126,726				101,275
Operating lease liability			35,057				35,767
Finance lease liability			66,926				68,109
Deferred tax liability, net			441				441
Other liabilities			33,105				31,740
Total liabilities			262,255				237,332
Stockholders' equity:
Preferred stock, $0.001 par value; 5,000 shares authorized; no    shares issued and outstanding as of September 30, 2026 and    December 31, 2025			-				-
Common stock, $0.001 par value; 150,000 shares authorized; 59,196    and 57,539 shares issued and 59,168 and 57,511 shares    outstanding at September 30, 2026 and December 31, 2025, respectively			59				58
Additional paid-in capital			1,684,829				1,586,056
Accumulated other comprehensive income			1,790				3,303
Accumulated deficit			(969,272	)			(933,130	)
Less treasury stock (28 shares as of September 30, 2026 and December 31,    2025)			(132	)			(132	)
Total stockholders' equity			717,274				656,155
Total liabilities and stockholders' equity		$	979,529			$	893,487

19

OCTOBER 28, 2026

Primary GAAP to Non-GAAP Reconciliations

GLAUKOS CORPORATION

GAAP to Non-GAAP Reconciliations

(in thousands, except per share amounts and percentage data)

(unaudited)

		Q3 2026												Q3 2025
		GAAP				Adjustments				Non-GAAP				GAAP				Adjustments				Non-GAAP
Cost of sales		$	31,164			$	(5,274	)	(A)	$	25,890			$	28,831			$	(7,310	)	(A)(B)	$	21,521
Gross Margin			85.2	%			2.5	%			87.7	%			78.4	%			5.5	%			83.9	%
Operating expenses:
Selling, general and administrative		$	130,943			$	(21,219	)	(C)(D)	$	109,724			$	82,999			$	243		(D)	$	83,242
Income (loss) from operations		$	828			$	26,493			$	27,321			$	(16,365	)		$	7,067			$	(9,298	)
Net income (loss)		$	2,018			$	26,493		(E)	$	28,511			$	(16,231	)		$	7,067		(E)	$	(9,164	)
Basic net income (loss) per share		$	0.03			$	0.45			$	0.48			$	(0.28	)		$	0.12			$	(0.16	)
Diluted net income (loss) per share		$	0.03			$	0.44			$	0.47			$	(0.28	)		$	0.12			$	(0.16	)
Weighted-average shares    outstanding used to    compute basic net income    (loss) per share			59,105								59,105				57,398								57,398
Weighted-average shares    outstanding used to    compute diluted net income    (loss) per share			61,196								61,196				57,398								57,398

(A)

•Cost of sales adjustment related to amortization of developed technology intangible assets associated with the acquisition of Avedro, Inc. (Avedro) of $4.8 million in Q3 2026 and $5.5 million in Q3 2025.

•Mobius acquisition-related amortization expense of developed intellectual property of $0.5 million in Q3 2026 and Q3 2025, respectively.

(B)

•Non-recurring, non-cash charge related to the write-down of certain inventory of $1.3 million.

(C)

•Expenses of $5.9 million related to the Company’s trade secrets litigation and other litigation matters.

•Expense of $14.1 million related to the resolution agreement with the Regents of the University of California.

•Expenses of $0.8 million associated with the integration of a major system.

(D)

•Mobius contingent consideration fair value adjustments of $0.4 million in Q3 2026 and ($0.2) million in Q3 2025.

(E)

•Includes total tax effect for non-GAAP pre-tax adjustments. For non-GAAP adjustments associated with the U.S., the tax effect is $0 given the Company's U.S. taxable loss positions in both 2026 and 2025.

20

OCTOBER 28, 2026

Primary GAAP to Non-GAAP Reconciliations

GLAUKOS CORPORATION

GAAP to Non-GAAP Reconciliations

(in thousands, except per share amounts and percentage data)

(unaudited)

		Year-to-Date Q3 2026												Year-to-Date Q3 2025
		GAAP				Adjustments				Non-GAAP				GAAP				Adjustments				Non-GAAP
Cost of sales		$	98,519			$	(19,222	)	(A)	$	79,297			$	80,043			$	(18,597	)	(A)(B)	$	61,446
Gross Margin			82.0	%			3.5	%			85.5	%			78.0	%			5.1	%			83.1	%
Operating expenses:
Selling, general and administrative		$	339,946			$	(26,316	)	(C)(D)	$	313,630			$	237,047			$	(52	)	(D)	$	236,995
(Loss) income from operations		$	(36,295	)		$	45,538			$	9,243			$	(59,732	)		$	18,649			$	(41,083	)
Non-operating income (expense):
Interest expense		$	(3,671	)		$	369		(E)	$	(3,302	)		$	(3,489	)		$	-			$	(3,489	)
Net (loss) income		$	(36,142	)		$	45,907		(F)	$	9,765			$	(54,034	)		$	18,649		(F)	$	(35,385	)
Basic net (loss) income per share		$	(0.62	)		$	0.79			$	0.17			$	(0.95	)		$	0.33			$	(0.62	)
Diluted net (loss) income per share		$	(0.62	)		$	0.78			$	0.16			$	(0.95	)		$	0.33			$	(0.62	)
Weighted-average shares    outstanding used to    compute basic net income    (loss) per share			58,651								58,651				57,083								57,083
Weighted-average shares    outstanding used to    compute diluted net income    (loss) per share (G)			58,651								60,598				57,083								57,083

(A)

•Cost of sales adjustment related to amortization of developed technology intangible assets associated with the acquisition of Avedro, Inc. (Avedro) of $17.8 million year-to-date Q3 2026 and $16.6 million year-to-date Q3 2025.

•Mobius acquisition-related amortization expense of developed intellectual property of $1.5 million year-to-date Q3 2026 and $0.7 million year-to-date Q3 2025.

(B)

•Non-recurring, non-cash charge related to the write-down of certain inventory of $1.3 million.

(C)

•Expenses of $9.9 million related to the Company’s trade secrets litigation and other litigation matters.

•Expense of $14.1 million related to the resolution agreement with the Regents of the University of California.

•Expenses of $1.2 million associated with the integration of a major system.

•Provision for doubtful accounts related to the overpayment of prior period payroll withholdings of $0.7 million.

(D)

•Mobius contingent consideration fair value adjustments of $0.4 million year-to-date Q3 2026 and ($0.2) million year-to-date Q3 2025.

•Mobius acquisition-related transaction expense of $0.3 million year-to-date Q3 2025.

(E)

•Interest expense related to the untimely payment of prior period payroll withholdings.

(F)

•Includes total tax effect for non-GAAP pre-tax adjustments. For non-GAAP adjustments associated with the U.S., the tax effect is $0 given the Company's U.S. taxable loss positions in both 2026 and 2025.

(G)

•Year-to-date Q3 2026 non-GAAP diluted weighted-average shares reflect the dilution effect from outstanding stock options, unvested restricted stock units, performance-based equity awards, and employee stock purchase program option shares under the treasury stock method.

21

OCTOBER 28, 2026

Additional GAAP to Non-GAAP Reconciliations

Reported Sales vs. Prior Periods (in thousands)
														Year-over-Year Percent Change												Quarter-over-Quarter Percent Change
		3Q 2026				3Q 2025				2Q 2026				Reported				Operations (1)				Currency (2)				Reported				Operations (1)				Currency (2)
International    Glaucoma		$	33,356			$	29,443			$	36,631				13.3	%			14.6	%			(1.3	%)			(8.9	%)			(8.4	%)			(0.5	%)
Total Net Sales		$	211,030			$	133,537			$	185,610				58.0	%			58.3	%			(0.3	%)			13.7	%			13.8	%			(0.1	%)

(1) Operational growth excludes the effect of translational currency

(2) Calculated by converting the current period numbers using the prior period’s average foreign exchange rates

For Non-GAAP disclosures associated with the company’s past quarterly results, included with respect to the sequential comparisons included herein, please see reconciliations here.

22

Filing Exhibits & Attachments

3 documents

Press Releases

• EX-99.1 EX-99.1 689.2 KB
• EX-99.2 EX-99.2 842.7 KB

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 23.3 KB